Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F X Gruber

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Journal of Thrombosis and Haemostasis : JTH|September 29, 2007
High tissue factor-expressing human monocytes carry low surface CD36: application to intersubject variabilityM A Sovershaev, E M Egorina, F X Gruber, et al.
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|October 18, 2001
[High dose therapy with autologous stem cell support--finally a progress in myelomatosis]F Wisløff, J M Tangen, L Brinch, et al.
Leukemia|May 3, 2016
Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patientsH Hjorth-Hansen, J Stentoft, J Richter, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Journal of Thrombosis and Haemostasis : JTH|September 29, 2007
High tissue factor-expressing human monocytes carry low surface CD36: application to intersubject variabilityM A Sovershaev, E M Egorina, F X Gruber, et al.
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|October 18, 2001
[High dose therapy with autologous stem cell support--finally a progress in myelomatosis]F Wisløff, J M Tangen, L Brinch, et al.
Leukemia|May 3, 2016
Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patientsH Hjorth-Hansen, J Stentoft, J Richter, et al.
Pageof 1